Comparison of characteristics of treated and non-treated patients with Hepatitis C infection

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 2, 2006, Pages 71-76

  Hare, C Bradley ^a   Morris, Jonathan A ^b   Chu, Alice ^b   Gotz, Vincent ^b   Loveland, Jacqueline J ^b   Hodes, David ^c   Klaskala, Winslow ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ProSanos Corporation   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

HBV co infection; Hepatitis C; HIV co infection; Medicaid

Indexed keywords

AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; ATTITUDE TO HEALTH; BODY WEIGHT; CHI SQUARE TEST; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENOTYPE; HEALTH CARE UTILIZATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL DECISION MAKING; MEDICAL RECORD; PATIENT ATTITUDE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SOCIOECONOMICS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; UNITED STATES; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADULT; AMBULATORY CARE FACILITIES; ANTIVIRAL AGENTS; DEMOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; MALE; MEDICAID; MEDICAL RECORDS; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SELECTION; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS;

EID: 33644636055     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1146     Document Type: Article

References (27)

1. Management of hepatitis C: 2002. NIH Consensus Development Conference Statement, vol. 19, 10-12 June 2002; 1-46.
2. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39.
3. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65S.
4. Alter MJ. Epidemiology of hepatitis C and lookback. Hematology (Am Soc Hematol Educ Program) 1999 Edition: 418-421.
5. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
6. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-961.
7. Davis GL. Current treatment for chronic hepatitis C. Rev Gastroenterol Disord 2001; 1: 59-72.
8. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
11. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
12. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
13. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
14. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
15. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-1061.
16. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-654.
17. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-598.
18. Bodenheimer HC, Jr., Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-477.
19. Reichard O, Norkrans G, Fryden A, et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-87.
20. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
21. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.
22. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and RBV on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-1137.
23. Management of Hepatitis C. NIH Consensus Statement, vol. 15, 24-26 March 1997; 1-41.
24. Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687-694.
25. Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37: 590-599.
26. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-215.
27. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med 1999; 14: 267-273.